How the mass spectrometry works in biopharmaceutical development?

Changes in blood platelets triggered by COVID-19 could contribute to the onset of heart attacks, strokes, and other serious complications in some patients who have the disease, according to University of Utah Health scientists.

The Rogers group and researchers at Shirley Ryan AbilityLab introduced a novel wearable device and set of data algorithms specifically tailored to catch early signs and symptoms associated with COVID-19 and to monitor patients as the illness progresses.

The Danaher Corp. company received emergency use authorization for its Access SARS-CoV-2 IgG test.

Sera Prognostics is developing a biomarker test for?predicting very preterm birth.

New research will help health-care practitioners to more accurately diagnose disease and illness in newborn babies from urine samples, according to a study by researchers at the University of Alberta and the Universidad Autónoma de Zacatecas.

The American Red Cross has begun testing all blood, platelet and plasma donations for COVID-19 antibodies.

BioFlyte said on Tuesday that it has raised $1.25 million in seed funding, which the company said it will use to accelerate the development of its mass spectrometry-based biothreat detection device.

Kidney disease diagnostics firm RenalytixAI announced Friday it has received a clinical laboratory permit from the New York State Department of Health allowing the company to provide its KidneyIntelX test to residents of the state.

HTG Molecular said on Thursday that it has signed three new European distribution agreements to promote its products and services in Nordic and Eastern Europe countries.

An international team led by investigators at the Max Planck Institute for the Science of Human History (MPI-SHH) and the National Museums of Kenya has uncovered population patterns going back thousands of years in sub-Saharan Africa

Cue Health announced Wednesday that it has raised $100 million in Series C financing.

MilliporeSigma and 10x Genomics announced on Wednesday a collaboration on single-cell CRISPR screening workflows.

CareDx said on Wednesday that it has priced a planned $125 million public stock offering at $32 per share.

Researchers at Johns Hopkins University have developed a gene editing approach they call very fast CRISPR (vfCRISPR) that is capable of creating double-strand breaks (DSBs) in seconds, and at the submicrometer scale.